...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN

SF

Thanks for sharing the information on Zenith Enigmatic, the mystical benefactor of RVX future royalties.

Not being insiders is most difficult for minority shareholders holding an interest in a non public company.

Hopefully the trial is progressing well and results are promising and we will get news soon.

I do believe that RVXs spinoff of Zenith and the company's award of a future revenue stream of 6-8% of all future RVX net revenues has hindered RVXs marketability. What was the real motive? Who was the architect? Why did DM tout a ZEN Market Cap of $500MM? What happened to the IPO, reverse IPO, BP partnership? 

And so many more questions -

So we patiently wait for enlightenment - 

My business responsibilites are pressing me right now and I don't have much time to correspond but I do keep current on everyones posts and the Agoracom daily digest is a helpful feature and reminder. 

Best Wishes to All,

Chicagoest 

Share
New Message
Please login to post a reply